Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that discontinuing finasteride led to a significant increase in sperm counts for most men with reduced fertility, though hormone levels and other semen parameters remained unchanged.

This study found that acute finasteride treatment decreased ethanol intake in male C57BL/6J mice, whereas chronic treatment showed diminished effects, implying compensatory changes in neurosteroid modulation.

This study examined different polymersome systems for topical finasteride delivery and found that chitosan-decorated C7 polymersomes may enhance skin retention and provide controlled drug release compared to non-decorated systems in laboratory settings.

This study observed that finasteride and spironolactone both led to a similar significant, but limited, improvement in hirsutism despite their differing effects on androgen levels.

In this study, 68% of patients treated with finasteride showed improved hair growth in male androgenetic alopecia, compared to 38% with Serenoa repens, indicating finasteride's superior efficacy.

Finasteride increases hair density in female androgenetic alopecia, but individual results may vary.

This study found that both high-dose and low-dose finasteride significantly reduced hirsutism scores in women after 12 months, with the lower dose being safe and cost-effective.

This study found that longer exposure to 5α-reductase inhibitors significantly increased the risk of persistent erectile dysfunction, especially in younger men exposed to finasteride.

This study found no evidence of androgen deficiency or decreased peripheral androgen action in men with persistent sexual symptoms after finasteride use, but identified links to depressed mood and abnormal brain function.

This study found that both topical and oral finasteride significantly reduced plasma DHT after one week, with lower finasteride plasma exposure for the topical formulation.

This study found that flutamide was more effective than finasteride in reducing hair growth in women with hirsutism over a one-year period.

This study found that a combination therapy of Diane 35 with finasteride was more effective at reducing hirsutism scores in women with idiopathic hirsutism or polycystic ovary syndrome after 3 months compared to Diane 35 alone.

Finasteride improves hidradenitis suppurativa but not for child-bearing women.

This study found that finasteride significantly reduced hirsutism scores in women with idiopathic hirsutism and PCOS, despite no changes in serum androgen levels.

This study observed that finasteride use among men with benign prostatic hyperplasia was associated with a decreased incidence of low-grade prostate cancer but not high-grade tumors.

This case report describes two infertile patients who experienced significant improvements in sperm concentrations six months after stopping finasteride.

This case report suggests that oral finasteride, used for benign prostatic hyperplasia, may be associated with intraoperative floppy-iris syndrome during cataract surgery.

Higher IGF-1 levels in hair follicles link to better finasteride results for hair loss.

In this study, both cyproterone acetate-estrogen combination (Diane®) and finasteride were effective in reducing hirsutism, but Diane® showed greater long-term efficacy and cost-effectiveness.

This study found that low-dose tamoxifen may effectively treat painful gynecomastia in patients receiving flutamide and finasteride for advanced prostate cancer.

This study found that polymeric nanoparticles may effectively deliver finasteride topically to hair follicles, potentially improving alopecia treatment with fewer side effects than oral forms.

This study found that the anticonvulsant effects of progesterone against PTZ-induced seizures in mice require conversion to allopregnanolone, as shown by the reversal of these effects with a 5alpha-reductase inhibitor.

This study found that liquid crystalline nanoparticles formulated with Cremophor surfactants significantly enhanced skin permeation of finasteride compared to lower surfactant concentrations.

This study found that finasteride competitively inhibits the enzyme AKR1D1 with low micromolar affinity but does not act as a mechanism-based inactivator.

This study found that the combination of spironolactone and finasteride significantly improved hirsutism scores more than spironolactone alone in women, with similar side-effect profiles between treatments.

This study found that progesterone pretreatment in rats potentiated the effect of ethanol on mesocortical dopamine levels, suggesting an influence of neuroactive steroids on ethanol's action.

This article contains additional supporting information available online but presents no new research findings.

This study found that finasteride at 1 mg/day was the most effective dose for treating male pattern hair loss, with similar efficacy to 5 mg/day and better results than lower doses.

This study found that overexpression of AKR1C3 in prostate cancer cells redirected androgen metabolism towards testosterone production, which facilitated cell proliferation, potentially reducing the effectiveness of finasteride treatment.

This study found that SRD5a-3 is a highly efficient enzyme for converting hormones into androgens, with dutasteride being a much more potent inhibitor of SRD5a-3 than SRD5a-2.